Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Ocular hyperaemia? 18 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Ocular hyperaemia have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 0.1% of all adverse event reports for CABOZANTINIB S-MALATE.

18
Reports of Ocular hyperaemia with CABOZANTINIB S-MALATE
0.1%
of all CABOZANTINIB S-MALATE reports
0
Deaths
3
Hospitalizations

How Dangerous Is Ocular hyperaemia From CABOZANTINIB S-MALATE?

Of the 18 reports, 3 (16.7%) required hospitalization.

Is Ocular hyperaemia Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB S-MALATE. However, 18 reports have been filed with the FAERS database.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Ocular hyperaemia?

DUPILUMAB (6,938) CYCLOSPORINE (1,508) BIMATOPROST (1,447) CENEGERMIN-BKBJ (1,226) BRIMONIDINE (917) ADALIMUMAB (714) LATANOPROST (587) DORZOLAMIDE\TIMOLOL (581) LIFITEGRAST (570) TRAVOPROST (478)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Ocular hyperaemia Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Ocular hyperaemia Reports All Drugs Causing Ocular hyperaemia CABOZANTINIB S-MALATE Demographics